On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Histogenics Corp. (NASDAQ: HSGX) Announces Publication of Data from Human Engineered Cartilage Testing; Shares Rise

Company: Histogenics Corp. (HSGX)
Category: News

Histogenics (NASDAQ: HSGX) this morning announced the online publication of biomechanical and structural data that analyzes mechanical properties of tissue engineered cartilage based on work done as part of a sponsored research agreement between Histogenics and Dr. Lawrence Bonassar at Cornell University. This was the first study to use three mechanical tests to examine and understand the performance of repaired cartilage in accordance with FDA guidance. Data from the study demonstrate Histogenics’ tissue engineered cartilage constructs exhibit mechanical properties approaching native human cartilage as early as three weeks in culture and prior to implantation. “The data generated in this study provide additional evidence of the importance of the combination of cells, engineering and scaffold to produce mechanically competent cartilage tissue implants with additional unique friction and compression properties that allow for proper function in vivo.  NeoCart’s unique ability to generate these characteristics prior to implantation is important, and we believe correlates nicely with the recently published clinical pain and functional data from the combined Phase 1 and 2 clinical trials for NeoCart.  Taken together, these results may indicate that tissue engineered implants, such as NeoCart, may enable a more rapid recovery and return to function for patients suffering from cartilage defects,” Histogenics CTO Stephen Kennedy stated in a news release.

To view the full press release, visit: http://nnw.fm/3eEDv

About Histogenics Corporation

Histogenics is a regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart, is currently in phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells.  Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217